February 4, 2013

Once-Daily Lyxumia® (lixisenatide) Approved for Treatment of Type 2 Diabetes in Europe

Sanofi portfolio expands to offer first once-a-day prandial GLP-1 receptor agonist

 

Once-Daily Lyxumia® (lixisenatide) Approved for Treatment of Type 2 Diabetes in Europe
Sanofi portfolio expands to offer first once-a-day prandial GLP-1 receptor agonist

Paris, France – February 4, 2013 – Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that the European Commission has granted Marketing Authorisation in Europe for Lyxumia® (lixisenatide). Lyxumia®, the first once-daily prandial GLP-1 receptor agonist, is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and / or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.